secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2026-09-08T20:06:07+00:00
Accession:  0001104659-26-105905
Event type: m_and_a
Sentiment:  negative
Materiality: 0.85
Item codes: 1.03, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo completes $50M asset sale to Eli Lilly, files July Chapter 11 operating report
--------------------------------------------------------------------------------

- Completed $50M asset sale to Eli Lilly on 9/4/26; includes STAC-BBB capsid, zinc finger, modular integrase platforms, and prion program ST-506.
- July 2026 MOR: cash $16.9M, assets $155.1M, liabilities $97.1M; pre-petition unsecured debt $78.1M, post-petition debt $19.0M.
- July operating report: net loss $11.2M for month, cumulative loss $14.9M; G&A $3.8M, reorganization items $4.2M.
- Chapter 11 filed 6/23/26; court approved sale 8/20/26; stock delisted from Nasdaq, trades OTC as SGMOQ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000110465926105905/0001104659-26-105905-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000110465926105905/tm2624942d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-105905

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer